Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma: A Pilot, Open Study

Trial Profile

Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma: A Pilot, Open Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
    • 07 Jun 2016 Results assessing the efficacy and safety of sorafenib in combination with gemcitabine + cisplatin presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 29 Feb 2016 Planned number of patients changed from 20 to 26 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top